ADVERTISEMENTs

Onconetix adds Ajith Singh to board of directors

Singh serves as an adjunct professor at the School of Medicine at Stanford, teaching clinical diagnostics and entrepreneurship

Ajith Singh / Image: LinkedIn

Cincinnati-based commercial stage biotech firm, Onconetix Inc. has appointed Ajit Singh to its board of directors, along with Dr Thomas Meier.

Singh is currently a partner at Silicon Valley-based Artiman Ventures, a firm focused on early-stage technology and life science investments with over US$ 1 billion in assets under management.

He also serves on the boards of Artiman Healthcare and Life Science Portfolio Companies, Sofie Biosciences, Leo Cancer Care, Artidis and Chronus Health, and is a member of the board of trustees of the American Association for Cancer Research (AACR) Foundation.

In addition, Singh serves as an adjunct professor at the School of Medicine at Stanford, teaching clinical diagnostics and entrepreneurship. He previously served as president and chief executive officer (CEO) of Biolmagene (acquired by Roche Pharmaceuticals) and as the global CEO of Siemens Oncology and Siemens Digital Imaging Systems.

Singh completed his B.Tech in electrical engineering from the Indian Institute of Technology (IIT) (Banaras Hindu University), Varanasi, MS in computer engineering from Syracuse University, and a doctorate in computer science from Columbia University.

Announcing the appointments, chairman of the board James Sapirstein, stated, "They bring enormous experience in the biotech industry to their roles, particularly in a commercial execution capacity, and we look forward to taking advantage of their knowledge as we move the company forward into a new era.”

The company focuses on research, development and commercialization of proprietary therapeutics, diagnostics and services for clinicians and patients for oncology.

 

Comments

ADVERTISEMENT

 

 

 

ADVERTISEMENT

 

 

E Paper

 

 

 

Video